Introduction
Achalasia is a rare primary esophageal motility disorder characterized by impaired lower esophageal sphincter (LES) relaxation, esophageal emptying dysfunction, and selective loss of inhibitory myenteric neurons. Despite decades of research, the initiating molecular mechanisms remain poorly understood, with genetic predisposition, viral infection, and immune dysregulation proposed as potential contributors. Previous genetic studies have been limited by small sample sizes, failing to identify definitive causal variants and establish clear links between genetic defects, immune dysregulation, and neuronal injury, which hinders the development of targeted therapies beyond symptomatic relief.
Aims & Methods
This study aimed to identify genetic variants linked to achalasia and clarify its underlying pathogenic mechanisms. We conducted the largest trio-based whole-genome sequencing (WGS) study to date, involving 22 proband-parent achalasia trios. To validate the functional significance of the identified variant, a CRISPR/Cas9-engineered Fam129c-mutant mouse model was established. Additionally, multi-omics analyses (bulk RNA-seq, single-cell RNA-seq, single-cell BCR-seq, and proteome profiling), time-course experiments, B cell depletion (via anti-CD20 antibodies), intravenous immunoglobulin (IVIG) treatment, tissue-based assays (TBA), and cell-based assays (CBA) were utilized to dissect the pathogenic process.
Results
A CRISPR/Cas9-engineered Fam129c-mutant mouse model recapitulated key features of achalasia, including growth retardation, elevated LES pressure, and selective loss of inhibitory neurons. Multi-omics analyses revealed substantial B cell expansion and activation within the LES, accompanied by enhanced humoral immune responses. Time-course experiments demonstrated that B cell accumulation preceded overt neuronal loss, while B cell depletion via anti-CD20 antibodies or intravenous immunoglobulin treatment partially rescued the phenotype. Further protein profiling and cell-based assays suggested that GABAA receptor may represent one potential neuronal antigen targeted by circulating autoantibodies.
Conclusion
Our study identifies FAM129C as a novel genetic susceptibility gene for achalasia and establishes a neuroimmune pathogenic mechanism, wherein FAM129C mutation drives B cell expansion and activation in the LES, leading to anti-GABAA receptor autoantibody secretion and subsequent inhibitory neuronal injury. These findings redefine achalasia as a neuroimmune-mediated disorder, highlight the potential of early-stage immunomodulatory interventions (anti-CD20 therapy, IVIG), and provide a framework for investigating the genetic-immune crosstalk in achalasia pathogenesis.